Introduction
Mineralocorticoids activate epithelial sodium channels in the distal nephron of the kidney through binding to mineralocorticoid receptors (MR), thereby promoting sodium reabsorption 1, 2) . Since glucocorticoids may also bind to MR and exert a mineralocorticoid-like action, some protection of MR from their promiscuous access may be needed. The selective binding of mineralocorticoids to MR depends on an enzyme, 11β -hydroxysteroid dehydrogenase (11 -HSD), which β catalyzes the conversion of cortisol in humans and corticosterone in rodents to their derivatives with low affinity to MR, cortisone, and 11 -dehydrocorti β -costerone, respectively 3, 4) . Types I and II 11 -HSD have been identified. β
Between them, type II 11 -hydroxysteroid dehydro β -genase (11 -HSD II) is co-localized with MR in the β kidney 5) , and its inhibition enhances sodium reabsorption in the distal nephron 6) . A congenital deficiency of 11 -HSD II results in a syndrome of ap β -parent mineralocorticoid excess 7) . Mice lacking 11 -β HSD II are hypertensive, along with marked hypertrophy and hyperplasia of the epithelium of the distal tubule in the kidney 8) .
However, the pathophysiological significance of the altered 11 -HSD activity has not been established in β various hypertensive models. In essential hypertension, the hypertension has been in part attributed to Internal Medicine Chonnam National University Medical School, Gwangju, Korea
The present study was aimed at investigating the role of type II 11 -hydroxysteroid dehydro β genase (II -β HSD II) in the development of hypertension. Two-kidney, one-clip (2K1C), deoxycorticosterone acetate (DOCA)/salt, or N G -nitro-L-arginine methyl ester (L-NAME) hypertension was induced in male SpragueDawley rats. Four weeks later, the expression of 11 -HSD II mRNA was determined in the kidney by β
Northern blot analysis. The plasma level of aldosterone was measured by radioimmunoassay. In 2K1C
hypertension, the expression of 11 -HSD II was decreased in the clipped kidney and increased in the β non-clipped kidney. The expression was increased in the remnant kidney of DOCA/salt hypertension, while decreased in the kidneys of L-NAME hypertension. The plasma level of aldosterone was increased, decreased, and remained unchanged in 2K1C, DOCA/salt, and L-NAME hypertension, respectively. The down-regulation of 11 -HSD II may contribute to the sodium retention, thereby increasing the blood β pressure in 2K1C and L-NAME hypertension. On the contrary, the up-regulation in DOCA/salt hypertension may play a compensatory role to dissipate the sodium retention. 10, 11) . In spontaneously hypertensive rats (SHR), one study showed an increase of 11 -HSD activity in the colon β and renal medulla 12) , another study failed to demonstrate alterations of its activity in the kidney 13) .
The present study was aimed at investigating the regulation of renal 11 -HSD II in various rat models of β Deoxycorticosterone acetate/salt hypertension was induced by subcutaneous implantation of silicone rubber containing DOCA (200 mg/kg), one week after unilateral nephrectomy. The rats were then supplied with 1.0% saline to drink. Its control group was also unilaterally nephrectomized and supplied with 1.0% saline to drink, but was without DOCA implantation. The third model of hypertension was made by treatment with L-NAME (100 mg/L drinking water). The control group was supplied with tap water without L-NAME.
They were kept for 4 weeks after inducing the hypertension. Systolic blood pressure was measured indirectly by tail-cuff method on the day of experiment. The trunk blood was collected by decapitation in a conscious state and then centrifuged at 1,500 g for 5 ×
min. The plasma concentration of aldosterone was measured using a commercial radioimmunoassay kit (Diagnostic Products; Los Angeles, CA, USA).
RNA isolation and analysis
After obtaining the trunk blood, the kidneys were rapidly removed. Total RNA was isolated using RNAzol solution according to the single-step method of
Chomczynski and Sacchi 14) . Results were expressed as mean SEM. The stati ± -stical significance of differences between the groups was determined using Student t-test.
Results
The blood pressure was significantly higher in the experimental group (Table 1) . The plasma level of aldosterone was increased in 2K1C hypertension and decreased in DOCA/salt hypertension, whereas it was not significantly changed in L-NAME hypertension (Table 1) .
The mRNA expression of 11 -HSD II was decreas β -ed in the clipped kidney, while increased in the non-clipped kidney in 2K1C hypertension (Fig. 1, 2) . It was increased in the remnant kidney of DOCA/salt hypertension (Fig. 3) , and decreased in the kidneys of L-NAME hypertension (Fig. 4) .
Discussion
Our study demonstrated an altered regulation of 11 -HSD II in the three models of secondary hyper β -tension. The mRNA expression of 11 -HSD II was β decreased in the clipped kidney of 2K1C hypertension and in the kidneys of L-NAME hypertension. On the contrary, the expression was increased in the nonclipped kidney of 2K1C hypertension and in the remnant kidney of DOCA/salt hypertension.
It has been shown that the activity and expression of 11 -HSD II are decreased in the kidney in Dahl β salt-sensitive hypertension and Lyon hypertension 16, 17) . Furthermore, 11 -HSD II (-/-) mice demonstrate β major features of the syndrome of apparent mineralocorticoid excess, along with striking hypertrophy and hyperplasia of the epithelium of the distal tubule 8) . It is likely that the down-regulation of 11 -HSD II has β increased the binding of glucocorticoids to MR, resulting in sodium retention and development of high blood pressure in 2K1C and L-NAME hypertension. On the other hand, it has been found that nephrectomy itself does not affect the expression of 11 -HSD II in β the remnant kidney 18) . Therefore, the up-regulation of 11 -HSD II in DOCA/salt hypertension may play a β compensatory role to dissipate the volume expansion and hypertension.
It has been well known that plasma renin activity and aldosterone concentrations are increased in 2K1C hypertension and suppressed in DOCA/salt hypertension. The present study also showed that the plasma level of aldosterone was increased in 2K1C hypertension, and decreased in DOCA/salt hypertension. On the contrary, it was not significantly altered in L-NAME hypertension. In the presence of aldosterone in vitro, the catalytic activity of 11 -HSD II is increased β in isolated renal cortical collecting ducts 19) . Administration L-NAME has been found to increase the plasma level of adrenocorticotropic hormone (ACTH) 21) . It was also demonstrated that ACTH dose-dependently decreased the expression and the enzyme activity of 11 -HSD II in human aortic endo β -thelial cells 22) . The down-regulation of 11 -HSD II in β the kidney may also in part be attributed to the release of ACTH in L-NAME hypertension in the present study. The renal expression of nitric oxide (NO) synthases was decreased in ACTH-and corticosterone-induced hypertension 23) . It has been well known that NO inhibits sodium reabsorption in the cortical collecting duct 24) . Taken together, L-NAME-induced hypertension may result from an interplay among NO, ACTH and 11 -HSD II. β
In summary, our study demonstrates an altered regulation of 11 -HSD II in the kidney in 2K1C, DOCA/ β salt, and L-NAME-induced hypertension. The downregulation of 11 -HSD II may contribute to the sodium β retention and subsequently to the elevation of blood pressure in 2K1C and L-NAME hypertension, whereas the up-regulation may play a compensatory role to dissipate the sodium retention in DOCA/salt hypertension.
